Document Detail


Simplification therapy with once-daily didanosine, tenofovir and efavirenz in HIV-1-infected adults with viral suppression receiving a more complex antiretroviral regimen: final results of the EFADITE trial.
MedLine Citation:
PMID:  16312178     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: High pill burden and side effects often impact on the long-term success of highly active antiretroviral therapy (HAART), which has led clinicians to search for more convenient regimens. Patients and methods: A prospective, multicentre, open, comparative study in which HIV-1-infected patients on HAART and with plasma HIV-1 RNA <50 copies/ml for longer than 6 months were switched to tenofovir, didanosine and efavirenz (QD arm) or remained on the same treatment regimen (control arm). Patients with grade 4 toxicities or plasma HIV-1 RNA values repeatedly >1000 copies/ml discontinued the study.
RESULTS: A total of 390 patients were included in the trial (309 in the QD arm and 81 in the control arm). The main baseline characteristics were well balanced between groups. In the QD arm, 41% of patients received high (standard) didanosine doses and 59% received reduced doses. At 12 months, plasma HIV-1 RNA <400 copies/ml was attained in 66% of QD patients and 73% of controls in the intent-to-treat (ITT) analysis (P=NS). However, the number of individuals with HIV-1 RNA <400 copies/ml in the QD arm was 56% versus 71% when comparing the use of high versus low didanosine doses (P=0.007). Treatment discontinuation occurred in 87 QD cases (28%) and 17 controls (21%). Twenty QD individuals (6.5%) and 2 controls (2.5%) discontinued because of virological failure (P=NS). The median CD4+ cell count change at 12 months was -26 and +27 cells/microl in QD patients and controls, respectively (P=0.001). In individuals who attained HIV-1 RNA <400 copies/ml, CD4+ cell changes were -25 and +15 cells/microl in QD patients and controls, respectively (P=0.001). Moreover, CD4+ cell declines in the QD arm were significantly greater in patients taking high versus low didanosine doses (-59 versus -15 cells/microl; P=0.04). The lipid profile improved significantly in the QD arm, particularly in patients who were on protease inhibitors prior to simplification.
CONCLUSIONS: Simplification to didanosine-tenofovir-efavirenz provides a virological suppression rate at 12 months similar to that seen in patients who do not change therapy, as long as low didanosine doses are administered. Decreases in CD4+ cell levels in patients in the QD arm (especially decreases seen with high didanosine doses) and dyslipidaemias along with less convenient pill burden and schedules in controls were the main long-term concerns for each option.
Authors:
Ana Barrios; Eugenia Negredo; Pere Domingo; Vicente Estrada; Pablo Labarga; Víctor Asensi; Dolores Morales; Jesús Santos; Bonaventura Clotet; Vincent Soriano;
Related Documents :
17227728 - Cytokine production from peripheral blood mononuclear cells in patients with ankylosing...
12186498 - Serum levels of tumor necrosis factor-alpha, soluble intercellular adhesion molecule-1,...
11099248 - Elevated plasma levels of matrix metalloproteinase-9 in patients with abdominal aortic ...
8600628 - Evaluation of recombinant human soluble dimeric tumor necrosis factor receptor for prev...
21725838 - Elevated serum igg4 is associated with chronic antibiotic-refractory pouchitis.
22666428 - Genetic analyses of heme oxygenase 1 (hmox1) in different forms of pancreatitis.
Publication Detail:
Type:  Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Antiviral therapy     Volume:  10     ISSN:  1359-6535     ISO Abbreviation:  Antivir. Ther. (Lond.)     Publication Date:  2005  
Date Detail:
Created Date:  2005-11-29     Completed Date:  2006-08-21     Revised Date:  2014-02-06    
Medline Journal Info:
Nlm Unique ID:  9815705     Medline TA:  Antivir Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  825-32     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenine / administration & dosage,  analogs & derivatives*,  therapeutic use
Adult
Anti-HIV Agents / administration & dosage*,  therapeutic use*
Antiretroviral Therapy, Highly Active
Benzoxazines
CD4 Lymphocyte Count
Didanosine / administration & dosage,  therapeutic use*
Dose-Response Relationship, Drug
HIV Infections / drug therapy*
HIV-1 / drug effects
Humans
Male
Middle Aged
Odds Ratio
Organophosphonates / administration & dosage,  therapeutic use*
Oxazines / administration & dosage,  therapeutic use*
Prospective Studies
RNA, Viral / blood
Treatment Outcome
Chemical
Reg. No./Substance:
0/Anti-HIV Agents; 0/Benzoxazines; 0/Organophosphonates; 0/Oxazines; 0/RNA, Viral; 107021-12-5/tenofovir; JAC85A2161/Adenine; JE6H2O27P8/efavirenz; K3GDH6OH08/Didanosine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Saquinavir 500 mg film-coated tablets demonstrate bioequivalence to saquinavir 200 mg hard capsules ...
Next Document:  Design and characterization of human respiratory syncytial virus entry inhibitors.